Agnete Brunsvik Fredriksen

Title: Agnete Brunsvik Fredriksen: Innovator in Immunology and Cancer Vaccines

Introduction

Agnete Brunsvik Fredriksen is a prominent inventor based in Raelingen, Norway. She has made significant contributions to the field of immunology, particularly in the development of innovative vaccines. With a total of eight patents to her name, Fredriksen is recognized for her groundbreaking work in enhancing immune responses and cancer treatment.

Latest Patents

Among her latest patents is the "HLA binding vaccine moieties and uses thereof." This invention relates to an immunoglobulin derived single-chain fragment variable (scFv) that broadly binds HLA II molecules. The targeting of an antigen to antigen presenting cells with the HLAII-specific targeting unit is designed to enhance immune responses after vaccination. Another notable patent is the "Therapeutic anticancer neoepitope vaccine." This invention includes polynucleotides or polypeptides and outlines methods for treating cancer using the vaccine. The vaccine comprises a polynucleotide with a nucleotide sequence encoding a targeting unit, a dimerization unit, a first linker, and an antigenic unit that includes multiple antigenic subunits.

Career Highlights

Fredriksen has worked with several notable companies in her career, including Vaccibody AS and Nykode Therapeutics ASA. Her work in these organizations has contributed to the advancement of vaccine technology and cancer immunotherapy.

Collaborations

Throughout her career, Fredriksen has collaborated with esteemed colleagues such as Bjarne Bogen and Inger Sandlie. These collaborations have further enriched her research and innovations in the field.

Conclusion

Agnete Brunsvik Fredriksen is a trailblazer in the development of vaccines aimed at improving immune responses and treating cancer. Her innovative patents and collaborations highlight her significant impact on the field of immunology.